Biomarkers of Induced Active and Passive Smoking Damage by Lodovici, Maura & Bigagli, Elisabetta
Int. J. Environ. Res. Public Health 2009, 6, 874-888; doi:10.3390/ijerph6030874 
 
International Journal of 
Environmental Research and 
Public Health 
ISSN 1660-4601 
www.mdpi.com/journal/ijerph 
Review 
Biomarkers of Induced Active and Passive Smoking Damage 
 
Maura Lodovici * and Elisabetta Bigagli 
 
Department of Pharmacology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy 
 
* Author to whom correspondence should be addressed; E-mail: maura.lodovici@unifi.it;  
Tel.: +390554271321 
Received: 23 December 2008 / Accepted: 20 February 2009 / Published: 26 February 2009 
 
Abstract:  In  addition  to  the  well-known  link  between  smoking  and  lung  cancer,  large 
epidemiological  studies have shown a relationship  between smoking and cancers  of the 
nose, oral cavity, oropharynx, larynx, esophagus, pancreas, bladder, kidney, stomach, liver, 
colon and cervix, as well as myeloid leukemia. Epidemiological evidence has reported a 
direct link between exposure of non-smokers to environmental tobacco smoke and disease, 
most notably, lung cancer. Much evidence demonstrates that carcinogenic-DNA adducts are 
useful  markers  of  tobacco  smoke  exposure,  providing  an  integrated  measurement  of 
carcinogen  intake,  metabolic  activation,  and  delivery  to  the  DNA  in  target  tissues. 
Monitoring accessible surrogate tissues, such as white blood cells or bronchoalveolar lavage 
(BAL) cells, also provides a means of investigating passive and active tobacco exposure in 
healthy individuals and cancer patients. Levels of DNA adducts measured in many tissues 
of  smokers  are  significantly  higher  than  in  non-smokers.  While  some  studies  have 
demonstrated  an  association  between  carcinogenic  DNA  adducts  and  cancer  in  current 
smokers, no association has been observed in ex or never smokers. The role of genetic 
susceptibility in the development of smoking related-cancer is essential. In order to establish 
whether smoking-related DNA adducts are biomarkers of tobacco smoke exposure and/or 
its carcinogenic activity we summarized all data that associated tobacco smoke exposure 
and smoking-related DNA adducts both in controls and/or in cancer cases and studies where 
the  effect  of  genetic  polymorphisms  involved  in  the  activation  and  deactivation  of 
carcinogens were also evaluated. In the future we hope we will be able to screen for lung 
cancer susceptibility by using specific biomarkers and that subjects of compared groups can 
be stratified for multiple potential modulators of biomarkers, taking into account various 
confounding factors. 
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1. Introduction 
 
Tobacco is the single most preventable cause of death in the world today, it has been estimated to 
have killed more than five million people in 2008 and will be responsible for the death of more than 
eight million by 2030 [1]. While many countries have adopted consistent policies against its use in 
public places, there are still approximately 1.3 billion smokers in the world and hundreds of millions 
of  smokeless  tobacco  users.  Cigarette  smoking  causes  30%  of  all  cancer  mortality  in  developed 
countries, and smokeless tobacco use is an important cause of cancer, particularly in southern Asia [2]. 
Tobacco smoke contains more than 4,000 chemicals and some of them are carcinogens. The strongest 
carcinogens present in tobacco smoke are polycyclic aromatic hydrocarbons (PAH), N-nitrosamines, 
aromatic amines, aldehydes, benzene and butadiene. Cigarette smoke products can be divided into 
particulate  and  gas  phases.  The  particulate  phase  contains  nicotine,  nitrosamines  [4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone],  N-nitrosonornicotine,  metals,  polycyclic  aromatic 
hydrocarbons  (PAH)  and  carcinogenic  amines  (4-aminobiphenyl).  The  gas  phase  contains  carbon 
monoxide,  carbon  dioxide,  benzene,  ammonia,  formaldehyde,  hydrogen  cyanide,  N-nitroso-
dimethylamine and N-nitrosodiethylamine [3]. 
In addition to the well-known link between smoking and lung cancer, large epidemiological studies 
have  shown  a  relationship  between  smoking  and  cancers  of  the  nose,  oral  cavity,  oropharynx, 
hypopharynx, larynx, esophagus, pancreas, bladder, kidney, stomach, liver, colon, cervix as well as 
myeloid  leukemia  [4].  Cigarette  smoking  predisposes  the  individual  to  several  different  clinical 
atherosclerotic syndromes, including stable angina, acute coronary syndromes, aortic and peripheral 
atherosclerosis sudden death, and stroke [5]. 
 
2. Environmental Tobacco Smoke  
 
In  1986  the  Surgeon  General  of  the  United  States  published  a  landmark  report,  based  on 
epidemiological evidence, asserting a direct link between exposure of non-smokers to environmental 
tobacco smoke and disease, most notably, lung cancer [6]. In the same year, the National Academy of 
Sciences  reported  similar  conclusion  regarding  the  adverse  effects  of  exposure  to  environmental 
tobacco smoke [7]. In 1997, the California Environmental Protection Agency published the final draft 
of a report regarding all known health effects of exposure to environmental tobacco smoke, including 
ischemic heart disease, lung cancer and bronchitis [8]. More than 50 studies on passive smoking and 
lung cancer risk in never smokers, especially spouses of smokers, have been carried out and published 
within the past 25 years. These studies show that there  is a statistically significant and consistent 
association between lung cancer risk in spouses of smokers and second-hand smoke from the spouse 
who smokes. This excess risk is on the order of 20% for women and 30% for men. The excess risk 
increases with increasing exposure [9]. It has been described that there is an increased risk of lower Int. J. Environ. Res. Public Health 2009, 6                 
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respiratory diseases in children of smoking parents and an increased risk of asthma [8]. The results 
from these reports have increased the debate on smoking and environmental tobacco smoke’s health 
impact  on  non-smokers  and  set  off  controversy  regarding  smoking  in  the  workplace  and  public 
buildings. Tobacco combustion results in the formation of mainstream smoke and sidestream smoke. 
Cigarette  smoke  that  is  drawn  through  the  tobacco  into  an  active  smoker’s  mouth  is  known  as 
mainstream  smoke.  Sidestream  cigarette  smoke  is  the  smoke  emitted  from  the  burning  end  of  a 
cigarette.  
Environmental tobacco smoke results from the combination of sidestream smoke (85%) and a small 
fraction  of  exhaled  mainstream  smoke  (15%)  from  smokers.  For  the  most  part,  the  chemical 
compositions of sidestream smoke and mainstream smoke are qualitatively similar and most toxic 
carcinogens are present in both of them but in different concentrations because of ageing and dilution 
with ambient air. Smokers who actively inhale very large doses of mainstream smoke-carcinogens, 
have a higher intake of carcinogens than environmental tobacco smoke-exposed individuals [10,11]. 
 
3. Environmental Exposure, Internal Dose and Biologically Effective Dose 
 
Molecular biomarkers are typically indicators of exposure effect or susceptibility [12]. A biomarker 
of exposure indicates the presence of exposure to an environmental agent while a biomarker of effect 
indicates the presence of a biological response to exposure to an environmental agent. Biomarkers thus 
have significant potential in clarifying the relationship between environmental agents and disease [13]. 
A  biomarker  of  exposure  requires  measurement  of  toxicant  levels  in  the  environment  and 
characterization of the individual presence, and interaction with that environment. But, a complexity 
arising  from  the  use  of  ambient  measurements  to  determine  exposure  status  of  individuals  is  the 
heterogeneous nature of most environmental contaminations. These measurements should be added to 
a system that integrates fluctuating exposures over time and relates time of exposure to dose. Given 
these problems of extrapolating ambient measurements to specific individual exposure, it has been 
well recognized that measures of the internal dose of a specific agent provide a clearer demonstration 
that a toxicant has been absorbed and possibly distributed in the body. Internal dose measurements are 
an  effective  identification  of  previous  exposure,  however,  they  do  not  provide  evidence  that 
toxicological  damage  has  occurred.  Among  the  various  possible  biomarkers  of  cancer  risk  is  the 
measurement of carcinogen-DNA adducts,  which are direct products of, or surrogate markers for, 
damage  to  critical  macromolecular  targets.  DNA  adduct  measurement  provides  an  integrated 
measurement of carcinogen intake, metabolic activation and delivery to the target macromolecule in 
target tissues (biologically effective dose) [14].  
Many  different  type  of  analytical  techniques  have  been  developed  to  measure  DNA  adducts, 
including 
32P-postlabeling  with  or  without  nuclease  P1,  immunoassay  using  antibodies  to  DNA 
adducts, physicochemical properties of adducts, such as fluorescence and mass spectrometry. Although 
each methodology has very different detection endpoints, the results obtained show a high quantitative 
similarity [15-17].  
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4. Biomarkers of Active and Passive Smoke Exposure 
 
Since  the  aim  of  this  review  is  the  evaluation  of  carcinogenic-DNA  adducts  as  biomarkers  of 
tobacco smoke exposure and its carcinogenic activity we reported studies that measured smoking-
related DNA adducts as biomarkers of tobacco smoke exposure both in cancer cases  and healthy 
smokers and non-smoker subjects [18-25]. The results obtained from these studies demonstrate that, as 
reported  in  Table  1A,  higher  DNA  adduct  levels  were  found  for  tobacco  smoke  exposure  (lung, 
bronchus, uterine cervix. etc.) in target organs from smokers than non smokers. Some of these authors 
also found a correlation between adduct levels  and smoke exposure [18,20]. In one study a good 
correlation was also found between DNA adducts and benzo(a)pyrene levels measured in lung tissue 
from smokers [24].  
 
Table 1A. Relationship between smoking and carcinogenic-DNA adducts in target organs 
due to tobacco smoke.  
Source of DNA  Methods  Higher  DNA  adducts  in  smokers 
than ex-and non-smokers 
Lung [18] 
 
Bladder [19] 
 
Lung [20] 
 
Uterine cervix [21] 
32P-postlabeling 
 
32P-postlabeling 
 
HPLC/fluorescence, 
32P-postlabeling 
 
32P-postlabeling 
29  cancer  cases  (17  smokers,  7  ex-
smokers, 5 non-smokers)  
 
39  healthy  subjects  (18 smokers,  21 
non-smokers) 
 
13  cancer  cases  (11  smokers,  2  ex-
smokers) 
 
16 HPV (10 smokers, 6 non-smoker) 
     
Lung [22] 
 
Pancreas [23] 
32P-postlabeling, fluorescence  
 
32P-postlabeling 
39 cancer cases (26 smokers, 11 ex-
smokers, 2 non-smokers)  
 
20 cancer cases (10 smokers, 10 non-
smokers) 
24 controls 
 
Lung [24]  HPLC/fluorescence   39  (12  smokers,  6  ex-smokers,  21 
non-smokers)  
 
Lung [25] 
 
HPLC/ECD detection of 8-oxo-dG  30 healthy subjects (14 smokers, 7 ex-
smokers, 9 non-smokers) 
 
When a surrogate tissue (white blood cells) was used, different results were observed from various 
laboratories. Some studies indicated a correlation between adduct levels in blood cells and lung as well 
as higher DNA adducts in smokers than in non smokers [26-28], while others demonstrate that white 
blood cells are not a good surrogate tissue [29,30] and still others that similar DNA adduct levels occur 
in blood cells from smokers and non-smokers [31,32], using 8-hydroxydeoxyguanosine as a marker of 
oxidative  DNA  damage  [25,33].  With  the  same  method  other  authors  [34,35]  report  a  significant Int. J. Environ. Res. Public Health 2009, 6                 
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increase in oxidative DNA damage in leukocytes from subjects exposed to  environmental tobacco 
smoke and a correlation between DNA damage and tobacco exposure, measured by plasma cotinine 
levels. Using DNA isolated from bronchoalveolar lavage (BAL) cells, DNA adduct levels were found 
to be significantly higher in smokers than in non-smokers [36-39]. But in 1992 Alexandrov et al. [20] 
published an important observation demonstrating that benzo[a]pyrenediol epoxide-DNA adducts were 
positively correlated with CYP1A1 enzyme activity in lung tissue of smokers. Later, many researchers 
focused  their  attention  on  the  effect  of  genetic  polymorphisms  involved  in  the  activation  and 
deactivation of carcinogens on risk damage to tobacco exposure.  
In our review we also considered studies that took into account the effect of genetic polymorphisms 
involved in the activation and deactivation of carcinogens on DNA adduct levels. For this reason, since 
major classes of carcinogens present in tobacco smoke are converted into DNA reactive metabolites by 
cytochrome P450-related enzymes, we reported studies that evaluated the effect of polymorphisms of 
CYPs  in  humans,  alone  or  in  addition  to  phase  II  enzymes,  particularly  glutathione  S-transferase 
(GST) on DNA adduct levels. These data are summarized in Table 1B. CYP1A1 is a phase I enzyme 
involved in the metabolic activation of aromatic amines and PAH and may affect the metabolism of 
environmental carcinogens and alter susceptibility to lung cancer. On the contrary, GST is a large 
family of phase II enzyme involved in xenobiotic detoxification. Butkiewicz et al. [40] found higher 
adduct levels in lung tissue from smokers lung cancer than non-smokers and a significant relationship 
between high adduct levels and the combined GSTM1 (null) and CYP1A1 polymorphic genotype. 
Similarly, Lewis et al. [41] reported that adduct levels tended to be higher in individuals with GSTM1 
null, GSTT1 null or GSTP1 wt genotypes in bronchial lavage samples while Peluso et al. [42] found 
no significant effect on DNA adducts and genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 in 
55 nasal brushing and bronchoscopies. Texeira et al. [43] reported that lymphocytes from smokers had 
significantly higher DNA adducts than non-smokers with a good correlation between the levels of 
DNA  adducts  and  the  number  of  cigarettes  smoked.  The  levels  of  DNA  adducts  in  smokers  is 
dependent on polymorphisms of CYP1A1 MspI. In fact, the allele variant of CYP1A1 MspI had DNA 
adducts about two-fold higher than CYP1A1 MpsI with no allele variant, but no effect was observed 
for the GST genotypes studied [43]. On the contrary, DNA adduct levels, adjusted for the number of 
cigarettes smoked per day, were found to be significantly higher in mononuclear blood cells from 
individuals with GSTM1 null than those with GSTM1 active [44]. In one study where smokers were 
divided into a high-risk group with CYP1A1 MspI and/or exon 7 Ile462Val allele variants, glutathione 
S-transferase M1 (GSTM1) null allele and wt glutathione S-transferase P1 (GSTP1), and a low-risk 
group  (wt  CYP1A1)  and  higher  deactivation  capacity  (active  GSTM1,  GSTP1  Ile105Val  allele), 
significantly lower BPDE-DNA adduct levels were reported in low-risk group [45]. Interestingly, Van 
Schooten et al., [46] found that MPO mutant genotypes are associated with reduced MPO activity in 
BAL fluid and reduced smoking-related DNA adduct levels in BAL cells in a gene-dose manner. 
Ketelslegers  et  al.  [47]  observed  that  GSTM1*0,  mEH*2,  and  GPX1*1  are  the  most  relevant 
polymorphisms for lymphocytic DNA adduct levels in smokers. Individuals having four risk alleles for 
these three genes had higher DNA adduct levels than individuals not possessing these particular risk 
alleles. However, recently Mollerup et al. [48] found lung DNA adducts highly related to CYP1A1 
expression, but irrespective of smoking-status in cancer cases. 
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Table 1B. Relationship between smoking and carcinogenic-DNA adducts in cancer-target 
organs due to tobacco smoke and influence of metabolic genotypes. 
Source of DNA  Methods  Elevated DNA adducts in 
smokers than non-smokers 
 
Lung [40] 
 
 
 
Lung [41] 
 
 
 
Lung [42] 
 
 
 
 
 
Lymphocytes [43] 
 
32P-postlabeling 
 
 
 
32P-postlabeling 
 
 
 
32P-postlabeling 
 
 
 
 
 
32P-postlabeling 
High  adduct  levels  associated 
with  CYP1A1  among  subjects 
with GSTM1 null  
 
High adducts in individuals with 
GSTM1  null,  GSTT1  null  or 
GSTP1 wt 
 
In  smokers  increased  adduct 
levels in both nasal mucosa and 
lymphocytes.  No  significant 
effect of CYP1A1, GSTM1 and 
GSTT1 
 
In smokers with CYP1A1 MspI 
allele variant. Adduct levels no 
influenced by GST genotypes 
 
Mononuclear cells [44] 
 
 
 
 
 
 
 
 
32P-postlabeling 
 
 
 
 
 
 
In  smokers  with  GSTM1  null 
(adjusted  for  the  amount  of 
cigarettes smoked per day) and 
in  slow  acetylators  for  both 
NAT1 and NAT2 with GSTM1 
null  than  fast  acetylator  with 
GSTM1 (+)  
Leukocytes [45] 
 
 
 
 
BAL fluid and cells [46] 
HPLC/fluorescence  
 
 
 
 
32P-postlabeling 
In  smokers  with  high  risk 
genotype  (CYP1A1  allele 
variant,  GSTM1  null,  and 
GSTP1 wt) 
 
In smokers with MPO wt than 
MPO  mutant  genotype.  The 
effect is gene dose-dependent 
 
 
Lymphocytes [47] 
 
 
Lung [48] 
32P-postlabeling 
 
 
32P-postlabeling 
In  smokers  with  GSTM1  null, 
mEH*2 and GPX1*1 
 
In  individuals  with  high 
CYP1A1  expression,  but 
irrespective  of  the  smoking 
status 
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5. Biomarkers of Tobacco Smoke Carcinogenic Activity 
 
In the molecular epidemiological literature carcinogen-DNA adducts are referred to as biomarkers 
of the biologically effective dose of a carcinogen and thus biomarkers of cancer risk. Carcinogen-DNA 
adducts represent the amount of carcinogen absorbed by the body that is not detoxificated, that is 
bound to cellular macromolecules and has not been repaired [49,50]. There is clear evidence that 
carcinogen-DNA adducts can reflect exposure to xenobiotics and there is clear mechanistic evidence 
that  carcinogen-DNA  adduct  formation  is  a  key  to  chemical  carcinogenesis  [51-53].  Recently,  a 
number  of  reviews  on  carcinogen-DNA  adducts  mention  epidemiological  studies  that  have 
investigated whether increased adduct levels are associated with cancer incidence [54-56]. A minority 
of these reports takes into account the limitations of this literature from an epidemiological point of 
view, eg. short half-lives of adducts, multiple exposures, weak effects and interactions with genetic 
susceptibility [53,55]. Veglia  et al. [55] conducted a meta-analysis of active smoking and cancer, 
including five studies of lung cancer [57-60,27], one of oral cancer [61] and one of bladder cancer [62] 
in which bulky DNA adducts were measured. They found a significant relationship between bulky 
DNA adducts and cancer in current smokers, while no association was observed in ex- and never 
smokers. The methods and results of the individual studies analyzed in the meta-analysis of Veglia et 
al. [55] are reported in Table 2A.  
 
Table 2A. Relationship between smoking-related DNA adducts in tissues of cancer cases 
and/or controls.  
Cancer  Methods  Relationship 
Lung [57]  PAH-DNA adducts (white blood cells) 
ELISA 
Strong OR= 7.7 (1.7-34) 
Lung [58] 
 
Lung [59] 
Bulky DNA adducts (lymphocytes) 
 
32P-postlabeling  
Bulky DNA adducts (lymphocytes)  
32P-postlabeling 
None 
 
Present 
Lung [60]  Bulky DNA adducts (lung tissue) 
32P-postlabeling  
Strong  OR=  25.19  (2.99-
211.99) 
Lung [27]   Bulky  DNA  adducts  (white  blood  cells) 
32P-postlabeling  
OR= 2.98 (1.05-8.42) 
Oral [61]  Bulky  DNA  adducts  (white  blood  cells) 
32P-postlabeling 
None 
Bladder [62]  Bulky DNA adducts ((white blood cells) 
32P-postlabeling  
Strong OR= 5.25 (2.21-12.43) 
Bladder [64]  Bulky DNA adducts (bladder tissue ) 
32P-postlabeling  
None Int. J. Environ. Res. Public Health 2009, 6                 
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Tale 2A. Cont. 
Lung, upper 
respiratory, bladder 
and leukemia [65] 
 
Bulky DNA adducts (white blood cells ) 
 
32P-postlabeling  
None  
Lung [66]  Bulky DNA adducts (white blood cells ) 
32P-postlabeling  
Present  
 
Hou et al. [58] found no association between carcinogen-DNA adducts and cancer in smokers but 
the only matching factor accounted for in these analyses was smoking. However, it was previously 
reported that failure to fully account for matching in a case-control study tends to bias results toward 
the  null  [63].  The  same  bias  was  also  present  in  the  study  of  Vulimiri  et  al.  [59]  that  found 
significantly higher carcinogen-DNA adducts in cases than in controls, although no statistical control 
for the matching variables was considered and the observed difference may be an underestimate of the 
effective differences. In addition to the studies included in the meta-analysis by Veglia et al. [55] data 
obtained from three other studies have been published on smoking-related cancers and carcinogen-
DNA adducts (Table 2A). 
Adduct levels in bladder tissue were measured by 
32P-postlabeling by Benhamou et al., [64] and no 
significant association was found between adducts and bladder cancer case-control status. However, 
smoking status was not taken into account in the data analysis. In the study of Peluso et al. [65] a 
relationship was observed between detectable adducts and lung cancer risk among never-smokers with 
OR = 4.04 (1.06-15.42), while adduct levels were not significantly associated with lung cancer in 
former-smokers. For the other cancers no association with detectable adduct levels was found [64]. On 
the contrary, Bak et al. [66] measured adduct levels in white blood cells from 255 randomly selected 
subjects considering sex, year of birth and smoking duration and demonstrated that among current 
smokers high adducts were significantly associated with lung cancer risk (incidence rate ratio (IRR) = 
1.61 (1.04-2.49) while high adduct levels, defined as being above the median level of the controls, 
were not.  
Although tobacco smoking is a well established risk factor for tobacco-related cancers, not all of 
those who have been exposed will develop disease, suggesting that there is individual variation in 
cancer susceptibility in  the  general  population  and  that  genetic polymorphisms  may modulate the 
association  observed  between  exposure  and  cancer  [67,3]  Some  of  the  most  widely  studied 
polymorphic  loci  are  those  coding  for  phase  I  and  II  enzymes  involved  in  the  activation  and 
conjugation  of  carcinogens  from  tobacco  smoke.  The  most  frequently  studied  include  CYP1A1, 
microsomal  epoxide  hydrolase  1  (mEH/EPHX1),  myeloperoxidase  (MPO),  NAD  (P)  H  quinone 
oxidoreductase 1 (NQO1) and the glutathione S-transferases (M1, P1 and T1), although others have 
also been studied [3]. Individuals with some genetic variants in the GST and CYP genes are reported 
to have different levels of PAH-DNA adducts in their lung tissue than those with wt genotype, and 
genetic  variants  have  been  extensively  studied  as  candidates  for  lung  cancer  susceptibility  as 
summarized in Table 2B. Ryberg et al. [68], analyzing 70 lung cancers, found higher DNA adduct Int. J. Environ. Res. Public Health 2009, 6                 
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levels in patients with the null GSTM1 genotype than in those with at least one intact GSTM1 allele. 
Moreover,  significantly  lower  adduct  levels  were  found  in  patients  with  the  polymorphic  GSTP1 
genotype (with higher affinity for PAH-diolepoxides) compared to those with the wild type GSTP1 
genotype.  The  same  results  were  obtained  by  Royas  et  al.  [69]  who  found  a  highly  significant 
difference  in  DNA  adduct  levels  between  lung  cancer  patients  with  GSTM1  null  and  those  with 
GSTM1 active genotype. On the contrary, Schoket et al. [70] reported no association between the 
combined CYP1A1 MspI and GSTM1 genotypes and DNA adduct levels in bronchial tissue from 150 
pulmonary surgery patients (126 with lung cancer). In one study analyzing 73 cancer cases Cheng et 
al. [60] found significantly high adducts levels than controls (33), but no association was observed 
with CYP1A1Msp1 or GSTM1 genotypes; on the contrary data reported by Li et al. [71] demonstrated 
an association between high adducts and CYP1A1 polymorphism in pancreatic cancer patients. 
 
Table 2B. Relationship between smoking-related DNA adducts in tissues of cancer cases 
and/or controls and effect of metabolic polymorphisms.  
Tissue  Methods  Number of subjects  Elevated DNA adducts and 
metabolic  polymorphism 
influence 
 
Lung [68] 
 
 
 
 
 
Lung [69] 
 
 
 
Bronchus [70] 
 
 
 
 
 
Lung [60] 
 
 
 
 
 
 
Pancreas [71] 
 
32P-postlabeling  
 
 
 
 
 
HPLC/fluorescence  
 
 
 
32P-postlabeling 
 
 
 
 
 
32P-postlabeling 
 
 
 
 
 
 
32P-postlabeling and 
HPLC/ECD  detection 
of 8-oxo-dG 
 
70 cancer cases (smokers)  
 
 
 
 
 
20 cancer cases (smokers) 
 
 
 
124  cancer  cases  (70 
smokers, 40 ex-smokers non-
smokers 14) 
26  controls  (12  smokers,  5 
ex-smokers, 9 non-smokers) 
 
73 cancer cases (32 smokers, 
38 non-smokers) 
33  controls  (11  smokers,  22 
smokers) 
 
 
 
31 cancer cases 
11 controls 
 
In patients with GSTM1 null 
or GSTP1 wt than those with 
GSTM1  positive  or  GSTP1 
polymorphic (n=70) 
 
 
In  patients  (n=20)  with 
GSTM1 null than those with 
GSTM1 (+) 
 
In  cancer  case  than  in 
controls. Adducts levels were 
not influenced by CYP1A1 or 
GSTM1 polymorphism 
 
  
In  cancer  cases  than  in 
controls,  but  not  higher  in 
smokers  than  non-smokers. 
Adducts  not  influenced  by 
CYP1A1Msp1  or  GSTM1 
genotypes  
 
In  cancer  cases  than  in 
controls. Association of DNA 
adducts  with  CYP1A1 
polymorphism  
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6. Conclusions 
 
The available data obtained from past decades show that DNA adduct formation is a key step in 
tobacco carcinogenesis, although the experimental evidence that carcinogen-DNA adducts are useful 
as biomarkers for evaluating the association between tobacco exposure and cancer risk is not always 
recognized. Hopefully in the future we will be able to screen individuals for cancer susceptibility by 
using specific biomarkers (for precise DNA adducts and metabolic polymorphisms) and then subjects 
can  be  stratified  for  multiple  potential  modulators  of  biomarkers,  taking  into  account  various 
confounding factors.  
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